Anxa1+ DANs show selective earlier loss compared to other dopaminergic neuron subtypes during PD progression.

Neuropathology Score: 0.500 Price: $0.50 Parkinson's disease mouse Status: extracted

What This Experiment Tests

Neuropathology experiment designed to assess clinical efficacy targeting Anxa1 in mouse. Primary outcome: Anxa1+ DANs show selective earlier loss compared to other dopaminergic neuron subtypes during PD pro

Description

Comparative analysis of neuronal loss across subtypes

TARGET GENE

Anxa1

MODEL SYSTEM

mouse

ESTIMATED COST

TIMELINE

0 months

PATHWAY

N/A

SOURCE

pmid_39763754

PRIMARY OUTCOME

Anxa1+ DANs show selective earlier loss compared to other dopaminergic neuron subtypes during PD progression.

Scoring Dimensions

Related Hypotheses (1)

Astrocyte C3aR Signaling as Bifurcation Point for A1/A2 Fate0.749

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.